Yong-yi I. Zeng - Publications

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.

Journal: Lancet (London, England)

Published: April 29, 2026

Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 24, 2026

Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study.

Journal: Gut

Published: February 10, 2026

Development and validation of the APTNM staging system: Integration of serum biomarkers with TNM classification for enhanced prognostic stratification following hepatectomy for hepatocellular carcinoma.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: November 18, 2025

Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: September 23, 2025

Development and validation of six-parameter laboratory-based prognostic model (APHPBA score) for patients undergoing hepatectomy for hepatitis B virus-related hepatocellular carcinoma.

Journal: HPB : the official journal of the International Hepato Pancreato Biliary Association

Published: September 17, 2025

Development and validation of an individualized online calculator for early mortality risk after hepatectomy among patients with HCC.

Journal: iLIVER

Published: September 15, 2025

Time to recurrence and BCLC stage at recurrence as critical variables in guiding treatment decisions for early-recurrent hepatocellular carcinoma after liver resection.

Journal: Frontiers in oncology

Published: July 24, 2025

Heterogeneity in prognosis for early-stage hepatocellular carcinoma after hepatectomy: A multicenter analysis of 4,623 patients across five major staging systems.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: May 29, 2025

Risk stratification model for predicting distant metastasis after hepatectomy for hepatocellular carcinoma: A multi-institutional analysis.

Journal: Bioscience trends

Published: March 05, 2025

Tumor biology characteristics score based on alpha-fetoprotein and protein induced by vitamin K absence or antagonist II as a predictor for recurrence and survival after curative resection for hepatocellular carcinoma: a multicenter cohort study.

Journal: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

Published: January 25, 2025

Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study.

Journal: BMC cancer

Published: November 09, 2024